Change - Announcement of Cessation::Resignation of Chief Financial Officer

Issuer & Securities

Issuer/ Manager
HYPHENS PHARMA INTERNATIONAL LIMITED
Securities
HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Cessation
Date &Time of Broadcast
06-May-2022 19:12:23
Status
New
Announcement Sub Title
Resignation of Chief Financial Officer
Announcement Reference
SG220506OTHRFVBK
Submitted By (Co./ Ind. Name)
Lim See Wah
Designation
Executive Chairman and Chief Executive Officer
Description (Please provide a detailed description of the event in the box below)
This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ( the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

Additional Details

Name Of Person
Fang Lee Wei
Age
47
Is effective date of cessation known?
Yes
If yes, please provide the date
13/06/2022
Detailed Reason (s) for cessation
Ms Fang Lee Wei ("Ms Fang") has resigned as the Chief Financial Officer ("CFO") to pursue other career opportunities.

After having interviewed Ms Fang and to the best of its knowledge, the Company's Sponsor, SAC Capital Private Limited, is satisfied that, other than as disclosed in this announcement, there are no other material reasons for the resignation of Ms Fang as CFO.

There are no concerns with regards to the financial reporting that led to the departure of Ms Fang and there are no disagreements between Ms Fang and the Board of the Company with regards to practices that will have an impact on the Company's financial reporting.

Whilst the Company is in the midst of identifying a replacement and will make the necessary announcement in due course, Mr Lim See Wah, Executive Chairman & CEO shall oversee the Group's financial management during this period and he will be assisted by Ms Serene Lim, Finance Director.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
No
Any other relevant information to be provided to shareholders of the listed issuer?
No
Date of Appointment to current position
01/01/2016
Does the AC have a minimum of 3 members (taking into account this cessation)?
Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
4
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
0
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Financial Officer
Role and responsibilities
Oversee the overall financial management of the Group.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
No
Shareholding interest in the listed issuer and its subsidiaries?
Yes
Shareholding Details
89,700 ordinary shares
Past (for the last 5 years)
NIL
Present
NIL